166 related articles for article (PubMed ID: 15753659)
1. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.
Shi R; Hong L; Wu D; Ning X; Chen Y; Lin T; Fan D; Wu K
Cancer Biol Ther; 2005 Feb; 4(2):218-24. PubMed ID: 15753659
[TBL] [Abstract][Full Text] [Related]
2. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.
Lin T; Liang S; Meng F; Han Q; Guo C; Sun L; Chen Y; Liu Z; Yu Z; Xie H; Ding J; Fan D
Clin Exp Immunol; 2006 May; 144(2):319-25. PubMed ID: 16634806
[TBL] [Abstract][Full Text] [Related]
4. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer.
Meng FP; Ding J; Yu ZC; Han QL; Guo CC; Liu N; Fan DM
World J Gastroenterol; 2005 Mar; 11(12):1833-6. PubMed ID: 15793876
[TBL] [Abstract][Full Text] [Related]
5. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
6. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
8. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
[TBL] [Abstract][Full Text] [Related]
9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
10. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
11. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
12. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
Stern BV; Boehm BO; Tary-Lehmann M
J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
[TBL] [Abstract][Full Text] [Related]
14. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
15. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
16. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route.
Ge W; Li Y; Li ZS; Zhang SH; Sun YJ; Hu PZ; Wang XM; Huang Y; Si SY; Zhang XM; Sui YF
Cancer Immunol Immunother; 2009 Feb; 58(2):201-8. PubMed ID: 18523770
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
[TBL] [Abstract][Full Text] [Related]
18. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
